6-K
Cuprina Holdings (Cayman) LTD (CUPR)
UNITEDSTATES
SECURITIESAND EXCHANGE COMMISSION
Washington,D.C. 20549
FORM6-K
REPORTOF FOREIGN PRIVATE ISSUERPURSUANT TO RULE 13a-16 OR 15d-16UNDER THE SECURITIES EXCHANGE ACT OF 1934
Forthe month of June 2025
CommissionFile Number: 001-42288
CuprinaHoldings (Cayman) Limited
(Registrant’sName)
c/oBlk 1090 Lower Delta Road #06-08
Singapore169201
(Addressof Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
| Form<br>20-F ☒ | Form<br>40-F ☐ |
|---|
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
InformationContained in this Form 6-K Report
On June 4, 2025, Cuprina Holdings (Cayman) Limited issued a press release providing update on the completion of Lab Able to Supply MEDIFLY Chronic Wound Therapy Across MENA Region, Secures Exclusive License to Market Medicinal Leeches in GCC Countries.
A copy of the press release dated June 4, 2025 is included as Exhibit 99.1 to this report.
FinancialStatements and Exhibits.
The following exhibits are being filed herewith:
| Exhibit No. | Description |
|---|---|
| 99.1 | Press Release on pricing, dated June 4, 2025. |
| 2 |
| --- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Cuprina Holdings (Cayman) Limited | |
|---|---|
| By: | /s/ David Quek Yong Qi |
| Name: | David<br> Quek Yong Qi |
| Title: | Director<br> and Chief Executive Officer |
Date: June 4, 2025
| 3 |
| --- |
Exhibit99.1
CuprinaCompletes Lab Able to Supply MEDIFLY Chronic Wound Therapy Across MENA
Region,Secures Exclusive License to Market Medicinal Leeches in GCC Countries
SINGAPORE,June 4, 2025 – Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“CUPR” or “the Company”), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today announced that its indirect 49%-owned associate, Cuprina MENA Co. Ltd, had completed the set-up of a laboratory, located in Saudi Arabia, equipped to manufacture the company’s MEDIFLY maggot debridement therapy for the treatment of chronic wounds and to supply the therapy across the Middle East and North Africa (“MENA”) region.
Cuprina MENA is now working towards obtaining the regulatory approvals, including the Saudi Food and Drug Authority license and ISO 13485 certification, required in order to sell the therapy in the MENA region.
In another development, Cuprina MENA has secured exclusive rights from Biopharm UK Ltd (“BioPharm”), the world’s leading provider of medicinal leeches, to sell these leeches across the Gulf Cooperation Council (“GCC”) countries.
Medicinal leeches are increasingly used in the GCC to treat diverse medical conditions including venous congestion, which is a buildup of blood in the veins, and to aid in tissue healing and circulation following reconstructive and microsurgery procedures. The leeches are also used to relieve symptoms of osteoarthritis as well as in veterinary surgery, especially to help treat polycythaemia vera, a chronic blood cancer.
“We are excited to complete both of these milestones,” said Cuprina chief executive David Quek. “These achievements, we believe, will help us to expand our market reach in the MENA and GCC regions, and add significant incremental revenue for our company.
“I look forward to sharing updates on these developments in the near future.”
AboutCuprina Holdings (Cayman) Limited
We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. For more information, please visit https:// www.cuprina.com.
AboutBiopharm UK Ltd
BioPharm is an international company based in Hendy, South Wales, UK. Established originally in 1812, it moved to its current base in 1984. BioPharm is the first leech farm of its kind and we are innovators in the cultivation of the medicinal leech, currently producing the majority of leeches used in modern medicine worldwide.
BioPharm is the pioneer in medical leech provision and has nurtured the renaissance of leeches in modern surgery. Our leeches are maintained in as sterile and pure environment as is possible; we continually invest in technology which includes ultraviolet light sterilization, reverse osmosis, activated carbon absorption and foam fractionating. These processes ensure that BioPharm Leeches are of the highest clinical standard. For more information, please visit https://www.biopharm-leeches.com
FORWARD-LOOKINGSTATEMENTS
Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the preliminary prospectus filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and Cuprina Holdings (Cayman) Limited specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
CuprinaHoldings (Cayman) Limited Investor Contact
Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email: [email protected]
InvestorRelations Inquiries:
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5^th^ Floor
New York, New York 10036
Office: (646) 893-5835
Email: [email protected]